The launch follows a randomized, double-blind study involving 138 women aged 40 to 60. Results published in Women's Health Reports indicate that participants experienced measurable relief from symptoms such as hot flashes and night sweats as early as 14 days into supplementation. At the 500 mg dosage, the study recorded up to a 61% reduction in hot flashes and a 51% decrease in night sweats, alongside improvements in sleep quality, mood, and hormonal markers like estradiol and follicle-stimulating hormone.

OmniActive utilized AI-based validation to refine the synergy between the two botanicals, ultimately standardizing the extract to 6% shatavarin IV and 4% protodioscin. According to Keya Shah, Senior Director of the Women’s Health Category, the product addresses a persistent lack of comprehensive, science-backed solutions for the full menopausal journey. The company plans to make the soy-free, hormone-free ingredient available to formulators later this year.